iDose TR (travoprost implant) — Medica

Initial criteria

• age ≥ 18 years
• not receiving re-treatment of eye(s) previously treated with iDose TR
• patient has tried at least two ophthalmic prostaglandins (either as monotherapy or as concomitant therapy) for the treatment of open-angle glaucoma or ocular hypertension
• patient has tried at least two other ophthalmic products (either as monotherapy or as concomitant therapy) from two different pharmacological classes for the treatment of open-angle glaucoma or ocular hypertension
• for each ophthalmic medication tried, patient had inadequate efficacy OR experienced adverse event(s) severe enough to warrant discontinuation
• administered by or under the supervision of an ophthalmologist

Approval duration

1 month (one-time use, one implant per treated eye; maximum two implants per patient)